secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2022-12-20T23:59:59+00:00
Accession:  0001193125-22-308821
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Magenta stops MGTA-117 Cohort 4 dosing after two DLTs; to continue at Cohort 3
------------------------------------------------------------------------------

- Three participants dosed in Cohort 4 (0.13 mg/kg); two had dose-limiting toxicities (respiratory SAEs).
- First DLT was Grade 4 respiratory SAE; second DLT triggered pre-specified stopping rules.
- No DLTs observed in fifteen participants across first three cohorts.
- Three of four Cohort 3 participants with paired samples showed cancer blast depletion in blood and bone marrow.
- Magenta reported first DLT to FDA; plans to enroll more patients at Cohort 3 (0.08 mg/kg).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312522308821/0001193125-22-308821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312522308821/d434259d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-308821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer